ArticleInsights into imaging2026
Diagnostic accuracy of a modified non-contrast O-RADS MRI scoring system: a retrospective study.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo develop a modified non-contrast O-RADS MRI scoring system and validate its diagnostic performance. MATERIALS AND
methodsThe modified non-contrast O-RADS MRI scoring system was developed by incorporating the significant signs from the standard O-RADS MRI system. This study retrospectively enrolled the 176 adnexal masses in cohort A. MRI imaging features were compared between benign and malignant tumors within this cohort. The diagnostic performance of the two scoring models was assessed by estimating the area under the curve (AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). In addition, 352 adnexal lesions from cohorts B and C were included to further evaluate the diagnostic ability of the modified scoring system.
resultsIn cohort A, the papillary projections exhibiting the sea anemone sign were highly indicative of borderline lesions (p = 0.001). Diffusion restriction in solid components significantly distinguished benign from malignant masses (p = 0.001). The apparent diffusion coefficient (ADC) value of cystic components yielded a cutoff of 1.74 (p < 0.05). The DeLong test revealed no statistically significant difference in AUCs between the two systems in cohort A (p > 0.05). The NRI and IDI for the modified non-contrast O-RADS MRI scoring system were -4.13% and -0.04, respectively (all p > 0.05). In cohorts B and C, the AUCs were 0.933 and 0.910.
conclusionThe diagnostic efficacy of the modified non-contrast O-RADS MRI scoring system was comparable to that of the standard O-RADS MRI risk stratification system, facilitating the distinction between benign and malignant adnexal neoplasms. KEY POINTS: Question How can a modified non-contrast O-RADS MRI scoring system be developed, and can this scoring system accurately classify adnexal masses? Findings The modified non-contrast O-RADS MRI system demonstrates excellent diagnostic performance and reliable risk stratification of adnexal masses by evaluating key imaging features. Critical relevance statement The modified non-contrast O-RADS MRI scoring system contributes to the risk stratification of adnexal masses, particularly for patients who cannot undergo contrast agent administration. This system provides a reliable tool to optimize treatment strategies and improve patient outcomes.
Indexed as
Identifiers
42886294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.